Literature DB >> 10765033

Comparative in vitro activity of S-4661, a new parenteral carbapenem, and other antimicrobial agents against respiratory pathogens.

A Watanabe1, H Takahashi, T Kikuchi, T Kobayashi, K Gomi, S Fujimura, Y Tokue, T Nukiwa.   

Abstract

The activity of S-4661, a new parenteral carbapenem antibiotic, was evaluated against 202 recent clinical isolates of respiratory pathogens. S-4661 was similar to or 2 times more active than imipenem, meropenem, and biapenem, and 8-128 times more active than ceftazidime against gram-positive bacteria. Against gram-negative bacteria, S-4661 was slightly less active than meropenem, but 2-8 times more active than the other agents. In particular, against Pseudomonas aeruginosa S-4661 showed the most potent activity. Thus it was found that S-4661 possesses a potent and well-balanced activity against respiratory pathogens. Copyright 2000 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10765033     DOI: 10.1159/000007276

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  11 in total

1.  In vitro antimicrobial activity of doripenem, a new carbapenem.

Authors:  Yigong Ge; Matthew A Wikler; Daniel F Sahm; Renée S Blosser-Middleton; James A Karlowsky
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

2.  In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates.

Authors:  Hannah M Wexler; Adrian E Engel; Daniel Glass; Calida Li
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

3.  Comparison of in Vitro Activity of Doripenem versus Old Carbapenems against Pseudomonas Aeruginosa Clinical Isolates from both CF and Burn Patients.

Authors:  Zoya Hojabri; Mohammad Ahangarzadeh Rezaee; Mohammad Reza Nahaei; Mohammad Hossein Soroush; Morteza Ghojazadeh; Tahereh Pirzadeh; Mostafa Davodi; Mona Ghazi; Reza Bigverdi; Omid Pajand; Mohammad Aghazadeh
Journal:  Adv Pharm Bull       Date:  2013-02-07

Review 4.  In vitro antibacterial activity of doripenem against clinical isolates from French teaching hospitals: proposition of zone diameter breakpoints.

Authors:  C Lascols; P Legrand; A Mérens; R Leclercq; L Armand-Lefevre; H B Drugeon; M D Kitzis; C Muller-Serieys; M E Reverdy; M Roussel-Delvallez; C Moubareck; A Lemire; A Miara; M Gjoklaj; C-J Soussy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-11-19       Impact factor: 3.267

5.  In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis.

Authors:  Yunhua Chen; Elizabeth Garber; Qiuqu Zhao; Yigong Ge; Matthew A Wikler; Koné Kaniga; Lisa Saiman
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

6.  Activities of doripenem (S-4661) against drug-resistant clinical pathogens.

Authors:  Ronald N Jones; Holly K Huynh; Douglas J Biedenbach
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

Review 7.  Comparative review of the carbapenems.

Authors:  George G Zhanel; Ryan Wiebe; Leanne Dilay; Kristjan Thomson; Ethan Rubinstein; Daryl J Hoban; Ayman M Noreddin; James A Karlowsky
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 8.  Doripenem: a review of its use in the treatment of bacterial infections.

Authors:  Susan J Keam
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.

Authors:  Chris M Pillar; Mohana K Torres; Nina P Brown; Dineshchandra Shah; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2008-09-08       Impact factor: 5.191

10.  Characteristics of doripenem: a new broad-spectrum antibiotic.

Authors:  Francisco Alvarez-Lerma; Santiago Grau; Olivia Ferrández
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.